Why is Krebs Biochem falling/rising?

As of 16-Jul, Krebs Biochemicals & Industries Ltd is experiencing a decline in its stock price, currently at 83.88, reflecting a change of -0.27 or -0.32%. The stock's performance today is described as inline with the sector, although it has shown erratic trading patterns, not trading on one day out of the last 20. While the stock is trading above its 5-day, 50-day, and 100-day moving averages, it remains below its 20-day and 200-day moving averages. The stock has seen a rise in investor participation, with a delivery volume increase of 41.99% against the 5-day average. However, the company has declared negative results for the last two consecutive quarters, with a negative book value and a high debt-to-equity ratio, indicating weak long-term fundamental strength. This has contributed to the stock's underperformance, with a -1.68% return over the past year and a consistent decline in profits.
In the broader market context, Krebs Biochem's short-term return of +1.97% over the past week contrasts with the Sensex, which has declined by -1.08% during the same period. However, the stock's long-term performance remains concerning, with a -13.23% return over the past month and a significant -16.20% decline over the last three years, underperforming against the benchmark consistently. The company's weak financial indicators, including a negative EBITDA and declining net sales growth, further exacerbate its challenges in the market. Overall, the combination of poor financial health and consistent underperformance against the benchmark suggests that the stock is facing significant headwinds.